Bavarian Nordic — Marts 2022
-
(Bava - Euroinvestor)
-
helt grotesk ift analytikeres holdning
-
Måske der alligevel bliver stærkt brug for Bavarians Covid vaccine, den er vel mere effektiv mod nye varianter end eksisterende vacciner
https://ing.dk/artikel/corona-varianter-stigende-grad-begyndt-at-udveksle-gener-lidt-gyser-255562? -
Ja hvis vi bare vidste om deres vaccine virker på Omikron variationen.
-
Carlsberg exit, Tesla stigning og bund i biotek? https://www.proinvestor.com/boards/102571
-
RSV Vaccine Candidate From BAVA Approaching the Starting Gate:
Compared to other development programs, the BAVA RSV vaccine (MVA-BN RSV) is the only RSV vaccine incorporating five different RSV antigens to stimulate a broad immune response against RSV subtypes (A and B) thus mimicking the immune response observed following a natural reaction to an RSV infection.
Ref to attached overview - despite the race of getting first to market there is clearly room for a lot of RSV development programs ()
-
() and BAVA is amongst the first out of the starting gate.
The global RSV therapeutics market was estimated at USD$ 1,111.3 million in 2019 and is projected to exceed USD$ 4,000 million by 2027. Considering BAVA has secured a partnership agreement for China and Asia shareholders are waiting patiently.
Good luck to all the shareholders!
Source: NFID - https://www.nfid.org/wp-content/uploads/2022/01/NFID-RSV-Call-to-Action.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind